Group B epidemic cerebrospinal meningitis fHbp-V2 recombinant protein, preparation method and applications of recombinant protein, and vaccine composition

A vaccine composition, a technology of fhbp-v2, applied in the field of vaccines, can solve the problems of low immunogenicity and cannot be used for research of group B meningococcal vaccine, etc., and achieves remarkable effect and the effect of preventing infection

Active Publication Date: 2020-02-21
BEIJING MINHAI BIOTECH
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Group B meningococcal meningitis cannot be used to study group B meningococcal vaccine because its capsular polysaccharide is an analogue of sialyl protein of human cells, resulting in low immunogenicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Group B epidemic cerebrospinal meningitis fHbp-V2 recombinant protein, preparation method and applications of recombinant protein, and vaccine composition
  • Group B epidemic cerebrospinal meningitis fHbp-V2 recombinant protein, preparation method and applications of recombinant protein, and vaccine composition
  • Group B epidemic cerebrospinal meningitis fHbp-V2 recombinant protein, preparation method and applications of recombinant protein, and vaccine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] The construction of embodiment 1.fHbp-V2 prokaryotic expression plasmid

[0035] 1.1. Obtain gene sequence

[0036] The nucleotide sequence of the fHbp-V2 gene as shown in seq ID NO.2 was obtained from the subvariant V2.18 strain of the fHbp gene of group B meningococcal meningitis preserved by the China Center for Disease Control and Prevention through conventional PCR gene amplification, The PCR primers used for amplification were: upstream primer: TGACCTGCCTCATTGATGC, downstream primer: GCCGTCCGAACACGATAATTTACCG, PCR conditions were pre-denaturation at 95°C for 5 minutes; denaturation at 95°C for 30s; annealing at 60°C for 30s; extension at 72°C for 60s; 30 cycles; 72°C After extension for 5min;

[0037] 1.2 Codon optimization:

[0038] In order to better express the target protein, remove the signal peptide nucleotide sequence of the fHbp gene shown in seq ID.NO.2 and use lasergene software to optimize the codon preference synthesis of E. coli to obtain the nucleo...

Embodiment 2

[0053] The establishment of embodiment 2.fHbp-V2 prokaryotic expression strain

[0054] The fHbp-V2 prokaryotic expression plasmid with correct sequencing was transformed into BL21(DE3) competent cells, spread on the LB solid medium containing kanamycin resistance, and picked the colony into a test tube containing 5ml liquid LB medium, 37 Cultivate on a shaker with a rotation speed of 180 rpm until the OD value of the bacterial solution reaches 0.2-0.4, add 5 μL of IPTG (isopropyl-β-D-thiogalactoside) to induce expression, and collect the bacteria at 12000 rpm after 3 hours of induction , resuspended with PBS solution and run SDS-PAGE protein electrophoresis to identify the expression of bacterial protein. image 3 Shown is the expression of fHbp-V2 prokaryotic expression protein strain.

Embodiment 3

[0055] Expression and purification of embodiment 3.fHbp-V2 recombinant protein

[0056] 3.1. Expression of fHbp-V2 recombinant protein

[0057] 1) Inoculate 50 μL of fHbp-V2 prokaryotic expression bacterial solution with high expression level into a test tube containing 10 mL of liquid LB medium, cultivate overnight at 37°C on a shaker with a rotation speed of 180 rpm, and inoculate into 2L of liquid LB culture medium the next morning cultured in cultured flasks.

[0058] 2) Cultivate until the OD value of the bacterial solution reaches 0.2-0.4, add 2 mL of IPTG to induce expression, and express for 20 hours at 16° C. on a shaker with a rotation speed of 180 rpm.

[0059] 3) The bacterial solution was centrifuged at 8000rpm for 30min, the bacterial cells were collected, and the bacterial cells were resuspended with 200mL of Tris solution with a pH of 7.5 and 30mM / L to form a bacterial cell suspension.

[0060] 4) Use a high-pressure homogenizer to crush the bacteria, the cru...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides group B epidemic cerebrospinal meningitis fHbp-V2 recombinant protein, a preparation method and applications of the recombinant protein, and a vaccine composition. A vaccine antigen protein gene is from group B epidemic cerebrospinal meningitis strains prevalent in China; and antigen protein immunized mice can induce binding antibody reaction with the average titer being 102600 and bactericidal antibody response for the group B epidemic cerebrospinal meningitis strains of fHbp-V2 and fHbp-V3, so that the infection caused by the group B epidemic cerebrospinal meningitis strains of the fHbp-V2 and fHbp-V3 genes can be prevented.

Description

technical field [0001] The invention belongs to the field of vaccines, and in particular relates to a group B meningococcal fHbp-V2 recombinant protein, the amino acid sequence of the recombinant protein, a gene encoding the recombinant protein, a vaccine composition comprising the recombinant protein, a preparation method of the recombinant protein, Use of the recombinant protein in preparing vaccines for preventing cerebrospinal meningitis or bacteremia diseases. Background technique [0002] Epidemic meningitis (referred to as meningitis) belongs to the Class B infectious disease stipulated in my country. It is a kind of respiratory transmission caused by Gram-negative Neisseria, with acute meningitis and sepsis as the main symptoms. Infants and adolescents are the main groups of infectious diseases. Neisseria meningitidis usually does not cause disease. It colonizes the nasopharynx of the human body in an asymptomatic form. In some cases, it can cause meningitis and Bacte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/22C12N15/31C12N15/70A61K39/095A61K39/39A61P31/04
CPCA61K39/095A61K39/39A61K2039/55505A61K2039/55566A61P31/04C07K14/22C12N15/70C12N2800/22
Inventor刘建东张静飞徐颖之张敬仁刘建凯郑海发
OwnerBEIJING MINHAI BIOTECH